Neurovance's Acquisition

Neurovance was acquired by Otsuka Holdings on March 02, 2017.

Neurovance is a privately held, clinical-stage pharmaceutical company focused on attention-deficit hyperactivity disorder (ADHD) and related disorders. Neurovance is developing centanafadine (CTN, for…

Articles about Neurovance's Acquisition: